Regeneron Pharma's (REGN) Buy Rating Reiterated at Deutsche Bank
Tweet Send to a Friend
Deutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) with a price target of $650. Earlier Regeneron and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
